MedTrace Logo

Nefazodone in the Treatment of Social Phobia

NCT00231348 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-11-13

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).

Conditions

  • Social Anxiety Disorder (SAD)

Interventions

DRUG

Nefazodone

Sponsors & Collaborators

Principal Investigators

  • Charles B Nemeroff, MD, PhD · Emory University Department of Psychiatry and Behavioral Sciences

  • Clinton D Kilts, PhD · Emory University Department of Psychiatry and Behavioral Sciences

  • Jeffrey Newport, MD · Emory University Department of Psychiatry and Behavioral Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Completion
2000-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00231348 on ClinicalTrials.gov